St Jude seeks US approval for smaller Angio-Seal
This article was originally published in Clinica
Executive Summary
St Jude Medical has applied for US marketing approval for a new size 6F Angio-Seal puncture closure device. The smaller version of the device will allow earlier discharge of heart patients following diagnostic cardiac catheterisation, says Kensey Nash, St Jude's partner and the company that developed Angio-Seal.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.